179055-28-8

Basic information

• Product Name: 4-(1-METHYL-1H-PYRAZOL-5-YL)BENZALDEHYDE
• Synonyms: 4-(1-METHYL-1H-PYRAZOL-5-YL)BENZALDEHYDE;Benzaldehyde, 4-(1-methyl-1H-pyrazol-5-yl)-;4-(2-METHYLPYRAZOL-3-YL)BENZALDEHYDE
• CAS NO: 179055-28-8
• Molecular Formula: C₁₁H₁₀N₂O
• Molecular Weight: 186.2099
• Mol File: 179055-28-8.mol

Chemical Properties

• Boiling Point: 350.215 °C at 760 mmHg
• Flash Point: 165.604 °C
• Appearance: /
• Density: 1.132 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.594
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(1-METHYL-1H-PYRAZOL-5-YL)BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1-METHYL-1H-PYRAZOL-5-YL)BENZALDEHYDE(179055-28-8)
• EPA Substance Registry System: 4-(1-METHYL-1H-PYRAZOL-5-YL)BENZALDEHYDE(179055-28-8)

Safety Data

• Hazardous Substances Data: 179055-28-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis and Pharmaceutical Research:
4-(1-METHYL-1H-PYRAZOL-5-YL)BENZALDEHYDE is utilized as a building block in the synthesis of various biologically active compounds. Its unique structure allows it to be a key component in the development of new pharmaceuticals, contributing to the advancement of medical treatments.
Used in the Food Industry:
As a flavoring agent, 4-(1-METHYL-1H-PYRAZOL-5-YL)BENZALDEHYDE is employed in the food industry to enhance the taste and aroma of various products. Its characteristic odor makes it a valuable ingredient in creating distinct flavors in food products.
Used in the Perfume Industry:
In the production of perfumes and other aromatic products, 4-(1-METHYL-1H-PYRAZOL-5-YL)BENZALDEHYDE serves as an intermediate. Its reactivity and aromatic properties make it an essential component in creating complex and long-lasting fragrances.
Used in the Production of Aromatic Products:
Beyond perfumes, 4-(1-METHYL-1H-PYRAZOL-5-YL)BENZALDEHYDE is also used in the creation of other aromatic products, such as candles, air fresheners, and cleaning products. Its ability to impart a pleasant scent and its reactivity in chemical processes make it a valuable asset in these industries.

InChI:InChI=1/C11H10N2O/c1-13-11(6-7-12-13)10-4-2-9(8-14)3-5-10/h2-8H,1H3

Upstream product

• 930-36-9 1-methyl-1H-pyrazole 
• 1122-91-4 4-bromo-benzaldehyde 
• 68-12-2 N,N-dimethyl-formamide 
• 73387-52-7 5-(4-bromophenyl)-1-methyl-1H-pyrazole 
• 99-90-1 para-bromoacetophenone 
• 179057-12-6 methyl 4-(1-methyl-1H-pyrazol-5-yl)benzoate 
• 114431-72-0 (E)-methyl 4-(3-(dimethylamino)acryloyl)benzoate 
• 38430-55-6 ethyl-4-acetylbenzoate 
• 179055-18-6 4-(2-methyl-2H-pyrazol-3-yl)benzyl alcohol 

Downstream Products

• 179055-67-5 Cycloheptyl-[4-(2-methyl-2H-pyrazol-3-yl)-benzyl]-amine 
• 179056-68-9 Benzyl-[4-(2-methyl-2H-pyrazol-3-yl)-benzyl]-amine 

Relevant articles and documents

2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS

The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; X1 and X2 are independently, at each occurrence, CR5 or N; Y is C1-C6 alkylene, wherein alkylene is optionally substituted with one to two C1-C3 alkyl groups; R1 is selected from the group consisting of hydrogen, halogen, C1-C6 alkoxy, -NH2, -NHR6, -NR7R8 and -NH-(R9)n-R10, n being 0 or 1; R2 is selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, -NH2, -NHR6, - NR7R8 and -NH-(R9)n-R10; R3 is selected from the group consisting of hydrogen, hydroxyl, OR11, -NR7R8, C1-C6 alkoxy, C1-C6 alkyl, C3-C10 cycloalkyl, C1-C3 haloalkyl, -C(O)NHR11, aryl, heteroaryl and heterocyclyl, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four Ra groups; and R4 is selected from the group consisting of -NH2, -N(R12)(V)pR13, - NH(V)p-OR14, -NHC(O)R15, and groups of formula la shown below, and their use in the treatment of diseases, in particular inflammatory diseases, cancer, stroke and/or Alzheimer's disease.

Palladium-catalysed direct diarylations of pyrazoles with aryl bromides: A one step access to 4,5-diarylpyrazoles

The palladium-catalysed direct arylation of pyrazoles with aryl halides, using PdCl(C3H5)(dppb)/KOAc catalyst, reveals a similar reactivity of C4 and C5 CH bonds of pyrazoles, whereas the C3 CH bond is almost unreactive, and gives ac

Pd-catalysed direct 5-arylation of 1-methylpyrazole with aryl bromides

1-Methylpyrazole was found to be a suitable partner for palladium-catalysed direct arylation through C-H activation/functionalisation using aryl bromides. The reaction conditions and the nature of the catalyst were found to have a determining influence on

Inhibitors of acyl-coA:cholesterol O-acyltransferase. 2. Identification and structure-activity relationships of a novel series of N-alkyl-N- (heteroaryl-substituted benzyl)-N'-arylureas

A series of N-alkyl-N-(heteroaryl-substituted benzyl)-N'-arylurea and related derivatives represented by 2 and 3 have been prepared and evaluated for their ability to inhibit acyl-CoA:cholesterol O-acyltransferase in vitro and to lower plasma cholesterol levels in cholesterol-fed rats in vivo. Among these novel compounds, the type 3 series was superior. A pyrazol-3-yl group on the N-benzyl group of this trisubstituted urea (i.e. 3, Ar1 = pyrazol-3- yl) was identified as a heteroaromatic ring providing a good profile of biological activity. As a result of optimization of the combination with the N-alkyl group (R) and N-aryl group (At3), compound 3aq (FR186054) was identified as a new, orally efficacious ACAT inhibitor, which exhibited potent in vitro ACAT inhibitory activity (rabbit intestinal microsomes IC50 = 99 nM) and excellent hypocholesterolemic effects in cholesterol-fed rats, irrespective of administration mode (ED50 = 0.046 mg/kg dosed via the diet, ED50 = 0.44 mg/kg administered by gavage in PEG400 vehicle). Moreover, a toxicological study revealed compound 3aq to be nontoxic to the adrenal glands of dogs when tested at a single dose of 10 mg/kg po.